Sirolimus monotherapy for Erdheim–Chester disease
2019; Taylor & Francis; Volume: 58; Issue: 6 Linguagem: Inglês
10.1080/0284186x.2019.1589648
ISSN1651-226X
AutoresEric F.H. van Bommel, Mark A. van der Zijden, P. J. H. Smak Gregoor, Tadek R. Hendriksz, Shiuw H. Ho-Han, Pieter J. Westenend,
Tópico(s)Myeloproliferative Neoplasms: Diagnosis and Treatment
ResumoErdheim–Chester Disease (ECD) is a rare, non-Langerhans histiocytosis, characterized by the accumulation of foamy macrophages, chronic inflammation, fibrosis and organ failure [1,2]. Interferon alf...
Referência(s)